MR/PET in the Evaluation of Patients With Esophageal Cancer

NCT02547610 | Unknown

• 1 other identifier: 201402050MINC
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

In this prospective study, we will recruit newly diagnosed esophageal cancer patients and perform MR/PET before and after chemoradiation therapy. In MR, new image sequences will be added to the conventional sequences, such as high resolution image, DWI, DCE, cine imaging.

Conditions

Esophageal Cancer

Keywords

MR/PET in the evaluation; patients

Outcome Measures

Primary Outcomes (1)

• The imaging biomarkers determined by MR-PET

  1 month

Interventions

The imaging biomarkers determined by MR-PET DEVICE

Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.

Eligibility Criteria

• Age: 20 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

In this prospective study, we will recruit newly diagnosed esophageal cancer patients and perform MR/PET before and after chemoradiation therapy.Total 80 patients will be recruited and followed after treatment complete for at least two years.

You may qualify if:

• newly diagnosed esophageal cancer patient
• age older than 20 years

You may not qualify if:

• For the safety reason, patients with the following conditions are contraindicated to enter magnetic resonance imaging (MRI) machine due to the high magnetic field, including: cardiac pacemaker, metallic artificial valve, intracranial and mediastinal vascular clips, cardiac defibrillator, nerve stimulator, implanted drug deliver system, metallic foreign body in the eye globe, cochlear implant, metallic fragments in the dangerous body part, Swan-Ganz catheter, and other metallic implants within 8 weeks: such as cardiac valve, stent, coil, filter, and clips.
• patient who will receive endoscopic local therapy alone
• unable to finish the standard surgical or radiation treatment
• history of surgery or radiotherapy to the mediastinum
• renal insufficiency, contraindication to MR imaging and contrast injection patient who have the severe allergic reaction the Gadollium contrast agent
• patient who have the claustrophobic symptoms are also not suitable for this MR examination
• pregnancy or lactating women

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Hospital

Taipei, Taiwan

RECRUITING

MeSH Terms

Conditions

Esophageal Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Study Officials

• Tiffany Ting-Fang Shih, M.D.

  Department of Medical Imaging, National Taiwan University Hospital.

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ting-Fang Shih, MD

CONTACT

+886-2-23123456; ttfshih@ntu.edu.tw

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 10, 2015
• First Posted: September 11, 2015
• Study Start: May 1, 2014
• Primary Completion: December 1, 2017
• Study Completion: April 1, 2018
• Last Updated: May 16, 2017

Record last verified: 2017-05

Locations

TW (1)